2014 Press Releases


Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
December 15, 2014
Xenon Pharmaceuticals Reports Third Quarter 2014 Financial Results
BURNABY, British Columbia, Dec. 15, 2014 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the third quarter ended September 30, 2014 and provided a corporate update. Dr. Simon Pimstone, Xenon's Pres... More >>
November 10, 2014
Xenon Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
BURNABY, British Columbia, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced initial public offering of 4,600,000 of its common shares at a price to the public of $9.00 per s... More >>
November 4, 2014
Xenon Pharmaceuticals Announces Pricing of Initial Public Offering
BURNABY, British Columbia, Nov. 4, 2014 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering of 4,000,000 of its common shares at a price to the public of $9.00 per share. In addition, Xen... More >>
March 26, 2014
Xenon and Genentech Establish New Pain Discovery Collaboration
Vancouver, Canada (March 26, 2014) – Xenon Pharmaceuticals Inc. today announced the establishment of a new collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for pain genetics, with the goal of discovering and validating new therapeutic targets and mechanisms for... More >>